|Bid||26.760 x 800|
|Ask||26.770 x 500|
|Day's Range||26.650 - 27.880|
|52 Week Range||10.040 - 28.450|
|PE Ratio (TTM)||1,275.24|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.
Gilead Sciences' CEO hints that buying a biotech with an oncology focus might not happen. Here's what this could mean for the big biotech.
Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”